Third course of immunotherapy and SBRT for head and neck cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests whether adding a third course of immunotherapy and focused radiation (SBRT) can help people with advanced head and neck cancer whose tumors have not shrunk after two initial rounds of treatment. It aims to see if this approach can improve outcomes with manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have advanced head and neck cancer (stage III or IV) that has not gotten worse or better after two cycles of chemotherapy and immunotherapy.
- You are in reasonably good health, able to care for yourself, and expected to live at least 3 more months.
- Your blood counts, kidney, liver, and heart function must be within certain safe limits.
- You cannot have active infections, autoimmune diseases, or other cancers that have been treated with radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (cetuximab, tislelizumab, and chemotherapy) in people with advanced head and neck cancer that hasn't been treated before. The goal is to see if this mix can shrink tumors and improve outcomes.
This trial tests whether combining radiation therapy with immunotherapy works better than immunotherapy alone for advanced head and neck cancer that hasn't been treated before. The goal is to help your body's immune system fight the cancer more effectively.
This trial is for people with advanced head and neck cancer who had good response to chemotherapy plus immunotherapy before surgery. It compares two different follow-up treatments: more immunotherapy or radiation therapy to help prevent cancer from coming back.
This trial looks at whether giving an immunotherapy drug (a PD-1 inhibitor) after surgery is better than giving radiation therapy for people with advanced head and neck cancer who had a complete response to chemotherapy and immunotherapy before surgery. The goal is to prevent the cancer from coming back.
This Phase 2 study tests whether giving low-dose radiation before surgery—along with chemotherapy and an immunotherapy drug—can work better and be safe for treating locally advanced head and neck squamous cell cancer. It may help shrink tumors before surgery and reduce the chance of the cancer coming back.
This trial tests whether giving tislelizumab (an immunotherapy) with chemotherapy before surgery works better than surgery alone for people with head and neck cancer that has not spread to lymph nodes. It's for cancers that can be removed with surgery, and the goal is to see if the pre-surgery treatment improves outcomes.
Hear when a new SBRT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.